Literature DB >> 15038601

The energetics of Huntington's disease.

Susan E Browne1, M Flint Beal.   

Abstract

Huntington's disease (HD) is a hereditary neurodegenerative disorder that gradually robs sufferers of the ability to control movements and induces psychological and cognitive impairments. This devastating, lethal disease is one of several neurological disorders caused by trinucleotide expansions in affected genes, including spinocerebellar ataxias, dentatorubral-pallidoluysian atrophy, and spinal bulbar muscular atrophy. HD symptoms are associated with region-specific neuronal loss within the central nervous system, but to date the mechanism of this selective cell death remains unknown. Strong evidence from studies in humans and animal models suggests the involvement of energy metabolism defects, which may contribute to excitotoxic processes, oxidative dmage, and altered gene regulation. The development of transgenic mouse models expressing the human HD mutation has provided novel opportunities to explore events underlying selective neuronal death in HD, which has hitherto been impossible in humans. Here we discuss how animal models are redefining the role of energy metabolism in HD etiology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15038601     DOI: 10.1023/b:nere.0000014824.04728.dd

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  139 in total

Review 1.  Nitric oxide, mitochondria, and cell death.

Authors:  G C Brown; V Borutaite
Journal:  IUBMB Life       Date:  2001 Sep-Nov       Impact factor: 3.885

2.  Neurotoxicity at the N-methyl-D-aspartate receptor in energy-compromised neurons. An hypothesis for cell death in aging and disease.

Authors:  R C Henneberry; A Novelli; J A Cox; P G Lysko
Journal:  Ann N Y Acad Sci       Date:  1989       Impact factor: 5.691

3.  1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers.

Authors:  B G Jenkins; H D Rosas; Y C Chen; T Makabe; R Myers; M MacDonald; B R Rosen; M F Beal; W J Koroshetz
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

4.  Reduction of glyceraldehyde-3-phosphate dehydrogenase activity in Alzheimer's disease and in Huntington's disease fibroblasts.

Authors:  J L Mazzola; M A Sirover
Journal:  J Neurochem       Date:  2001-01       Impact factor: 5.372

5.  Huntington's disease progression. PET and clinical observations.

Authors:  T C Andrews; R A Weeks; N Turjanski; R N Gunn; L H Watkins; B Sahakian; J R Hodges; A E Rosser; N W Wood; D J Brooks
Journal:  Brain       Date:  1999-12       Impact factor: 13.501

6.  Decreased expression of striatal signaling genes in a mouse model of Huntington's disease.

Authors:  R Luthi-Carter; A Strand; N L Peters; S M Solano; Z R Hollingsworth; A S Menon; A S Frey; B S Spektor; E B Penney; G Schilling; C A Ross; D R Borchelt; S J Tapscott; A B Young; J H Cha; J M Olson
Journal:  Hum Mol Genet       Date:  2000-05-22       Impact factor: 6.150

7.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.

Authors:  J S Steffan; L Bodai; J Pallos; M Poelman; A McCampbell; B L Apostol; A Kazantsev; E Schmidt; Y Z Zhu; M Greenwald; R Kurokawa; D E Housman; G R Jackson; J L Marsh; L M Thompson
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

8.  Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate.

Authors:  M F Beal; D R Henshaw; B G Jenkins; B R Rosen; J B Schulz
Journal:  Ann Neurol       Date:  1994-12       Impact factor: 10.422

9.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

Authors:  Alexander V Panov; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden; James R Burke; Warren J Strittmatter; J Timothy Greenamyre
Journal:  Nat Neurosci       Date:  2002-08       Impact factor: 24.884

10.  Widespread expression of Huntington's disease gene (IT15) protein product.

Authors:  A H Sharp; S J Loev; G Schilling; S H Li; X J Li; J Bao; M V Wagster; J A Kotzuk; J P Steiner; A Lo
Journal:  Neuron       Date:  1995-05       Impact factor: 17.173

View more
  86 in total

Review 1.  Antioxidants in Huntington's disease.

Authors:  Ashu Johri; M Flint Beal
Journal:  Biochim Biophys Acta       Date:  2011-11-23

2.  Huntington's disease and mitochondrial alterations: emphasis on experimental models.

Authors:  Verónica Pérez-De la Cruz; Paul Carrillo-Mora; Abel Santamaría
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

3.  Carnosic Acid Suppresses the H2O2-Induced Mitochondria-Related Bioenergetics Disturbances and Redox Impairment in SH-SY5Y Cells: Role for Nrf2.

Authors:  Marcos Roberto de Oliveira; Gustavo da Costa Ferreira; Alessandra Peres; Simone Morelo Dal Bosco
Journal:  Mol Neurobiol       Date:  2017-01-13       Impact factor: 5.590

Review 4.  Energy deficit in Huntington disease: why it matters.

Authors:  Fanny Mochel; Ronald G Haller
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

5.  Truncated peroxisome proliferator-activated receptor-γ coactivator 1α splice variant is severely altered in Huntington's disease.

Authors:  Ashu Johri; Anatoly A Starkov; Abhishek Chandra; Thomas Hennessey; Abhijeet Sharma; Sara Orobello; Ferdinando Squitieri; Lichuan Yang; M Flint Beal
Journal:  Neurodegener Dis       Date:  2011-07-15       Impact factor: 2.977

6.  Comparison of analytical mathematical approaches for identifying key nuclear magnetic resonance spectroscopy biomarkers in the diagnosis and assessment of clinical change of diseases.

Authors:  Jason B Nikas; C Dirk Keene; Walter C Low
Journal:  J Comp Neurol       Date:  2010-10-15       Impact factor: 3.215

Review 7.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

8.  Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage.

Authors:  Rosilla F Bachmann; Yun Wang; Peixiong Yuan; Rulun Zhou; Xiaoxia Li; Salvatore Alesci; Jing Du; Husseini K Manji
Journal:  Int J Neuropsychopharmacol       Date:  2009-01-19       Impact factor: 5.176

9.  Impaired brain energy metabolism in the BACHD mouse model of Huntington's disease: critical role of astrocyte-neuron interactions.

Authors:  Lydie Boussicault; Anne-Sophie Hérard; Noel Calingasan; Fanny Petit; Carole Malgorn; Nicolas Merienne; Caroline Jan; Marie-Claude Gaillard; Rodrigo Lerchundi; Luis F Barros; Carole Escartin; Thierry Delzescaux; Jean Mariani; Philippe Hantraye; M Flint Beal; Emmanuel Brouillet; Céline Véga; Gilles Bonvento
Journal:  J Cereb Blood Flow Metab       Date:  2014-06-18       Impact factor: 6.200

10.  Bioenergetic analysis of isolated cerebrocortical nerve terminals on a microgram scale: spare respiratory capacity and stochastic mitochondrial failure.

Authors:  Sung W Choi; Akos A Gerencser; David G Nicholls
Journal:  J Neurochem       Date:  2009-03-23       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.